Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Archivos de cardiología de México
versión On-line ISSN 1665-1731versión impresa ISSN 1405-9940
Arch. Cardiol. Méx. vol.76 no.4 Ciudad de México oct./dic. 2006
Investigación clínica
Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction
Alteraciones de la perfusión miocárdica y marcadores de inflamación en pacientes con infarto agudo al miocardio tratados con angioplastía primaria
J Emilio Exaire,* Robert B Fathi,** Sorin J Brener,** Juhana Karha,** Stephen G Ellis,** Deepak L Bhatt**
1 Instituto Nacional de Cardiología, Mexico City, Mexico.
2 The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH.
Correspondence to:
Dr. J. Emilio Exaire.
Adjunto Departamento de Hemodinámica y Cardiología Intervencionista.
Instituto Nacional de Cardiología "Ignacio Chávez". (INCIH, Juan Badiano Núm. 1 Col. Sección XVI, Tlalpan
14080 México, D.F.)
Email: jeexaire@yahoo.com
Recibido: 15 de junio de 2005
Aceptado: 27 de Julio de 2006
Summary
Background: Microcirculatory dysfunction during acute myocardial infarction is mediated by various mechanisms including inflammation, thrombus, or plaque embolization. We hypothesize that patients with acute myocardial infarction and admission Thrombolysis in Myocardial Infarction (TlMl) myocardial perfusión grade (TMP) < 2 had increased inflammatory status as measured by high sensitivity Creactive protein (hsCRP).
Methods: From January 2002 to December 2003, 166 patients (178 lesions) were referred for primary percutaneous coronary intervention. Patients were stratified based on prePCI TMP < 2 or TMP 3 2. Univariate and multivariate predictors of inhospital and 30day death were determined with logistic regression.
Results: PrePCI TMP < 2 was found in 66% vs 34% with TMP 3 2 (P < .001). HsCRP levels were high in both groups but not significantly different (37.9 ± 6 vs 33.7 ± 6 mg/L, P = .63). Patients with TMP < 2 had higher WBC (12.83 ± 4.55 * 103 vs 10.83 ± 3.00 * 103, P = .04), lower ejection fraction (40 ± 11% vs 46 ± 12%, P < .001), and higher admission CKMB levels (116 ± 13 ng/mL vs 55 ± 13 ng/mL, P = .006). Death occurred in 12% in the poor TMP group vs 1.8% in the good TMP group (P = .03). Advanced age, use of an intraaortic balloon pump, and elevated admission WBC were independently associated with inhospital and 30day death.
Conclusions: High hsCRP levels were not associated with impaired myocardial perfusión score. Microcirculatory impairment may be related to an increased inflammatory process, independent from high hsCRP levels.
Key words: Percutaneous intervention. Myocardial infarction. Inflammation.
Resumen
Objetivos: La disfunción de la microcirculación coronaria durante el infarto agudo al miocardio es mediada por varios mecanismos incluyendo inflamación y embolización de placa y/o trombo. La hipótesis del presente estudio es que los pacientes con infarto agudo al miocardio que se presentan con niveles bajos de perfusión microcirculatoria (definidos como grado de perfusión Thrombolysis in Myocardial Infarction (TIMI) (TMP) < 2) tienen un aumento en los marcadores inflamatorios, tales como proteína Creactiva de alta sensibilidad (hsCRP) y glóbulos blancos, y la correlación de estos niveles con la mortalidad de esta cohorte.
Métodos: De enero de 2002 a diciembre de 2003, 166 pacientes (178 lesiones) fueron referidos para intervención percutánea. Los pacientes fueron estratificados para este análisis en TMP < 2 o TMP 3 2. Los factores asociados a mortalidad intrahospitalaria fueron determinados con análisis de regresión logística.
Resultados: Un TMP < 2 preintervención fue encontrado en 66% vs 34% de los pacientes (P < .001). Los niveles de hsCRP se encontraron elevados en ambos grupos pero no significativamente diferentes (37.9 ± 6 vs 33.7 ± 6 mg/L, P = 0.63). Los pacientes con TMP < 2 tuvieron cuentas de glóbulos blancos mayores (12.83 ± 4.55 * 103 vs 10.83 ± 3.00 * 103, P = .04), menor fracción de expulsión (40 ±11% vs 46 ± 12%, P < .001), y mayores niveles de CKMB a la admisión (116 ± 13 ng/mL vs 55 ± 13 ng/mL, P = .006). La muerte ocurrió en 12% del grupo TMP <2 vs 1.8% en el grupo con TMP > 2 (P = .03). La edad avanzada, el uso de balón de contrapulsación y los niveles elevados de glóbulos blancos al momento de la admisión se relacionaron independientemente con la muerte intrahospitalaria y a 30 días.
Conclusiones: Los niveles elevados de hsCRP no se asociaron con disfunción de la microcirculación. La disfunción microcirculatoria puede estar relacionada a un proceso inflamatorio, independiente de los niveles elevados de hsCRP.
Palabras clave: Intervención percutánea. Infarto del miocardio. Inflamación.
Inflammation plays a central role in cardiovascular disease. Elevated levels of Creactive protein and white blood cell count (WBC) have been unequivocally associated with adverse outcome in patients with stable and unstable coronary syndromes as well as stroke.1,17 However, the impact of an increased inflammatory milieu, such as acute myocardial infarction (AMI),4,1830 on a microcirculation surrogate such as Thrombolysis in Myocardial Infarction (TIMI) perfusión (TMP) grade has not been entirely elucidated.3134 Thus, we sought to analyze the potential role of inflammation markers on the microcirculation, as measured by admission TMP, as well as its impact on postpercutaneous coronary intervention (PCI) shortterm mortality.
Methods
From January 2002 to December 2003, 166 patients (178 lesions) were referred to the Cleveland Clinic Foundation for primary PCI. Demographic and clinical information, procedural technique, and major adverse cardiac events (MACE) (including death or reinfarction during hospitalization and 30day followup), preand postprocedural creatine kinase (CK), and CKMB, high sensitivity CRP levels (hsCRP), and WBC were recorded prospectively. All patients had clinical and electrocardiographic criteria of acute STsegment elevation MI. All patients received aspirin, loading doses of Clopidogrel (300 mg) and 75 mg thereafter, and GP Ilb/IIIa inhibitors (abciximab 88%; other 12%). Univariate and multivariate predictors of inhouse and 30day death were determined with logistic regression.
Two independent experienced blinded operators assessed the pre and postPCI TMP score according to the established TIMI grading system34,35 obtaining an interobserver correlation of 98%. TMP 0 was defined as failure of dye to enter the microvasculature (no groundglass appearance). TMP 1 was defined as dye slowly entering the microvasculature and failing to exit. TMP 2 was defined as delayed entry and/or exit from the microvasculature (persisting after 3 cardiac cycles). TMP 3 was defined as normal entry and exit of dye from the microvasculature. Patients were stratified based on prePCI TMP < 2 orprePCITMP > 2.
Continuous variables were compared using Student's t test if normally distributed and Wilcoxon ranksum if not. Binary variables were compared using with normal approximation or Fisher's exact test when appropriate. A 2tailed P value of 0.05 was considered significant. In order to analyze the variables associated with postPCI death a stepwise logistic regression model was performed.
Results
Both groups were similar regarding most admission characteristics (Table I). However, patients with prePCI TMP < 2 had higher WBC (12.83 ± 4.55 * l03 vs 10.83 ± 3.00 * l0"3, P = .04), lower ejection fraction as measured by echocardiography (40 ± 11% vs 46 ± 12%, P = .001), and higher CKMB levels (116 ± 13 ng/mL vs 55 ± 13 ng/mL, P = .006). HsCRP levels were high in both groups but not statistically different (37.9 ± 6 vs 33.7 ± 6 mg/ L, P = .63). Death occurred in 12% (N = 13) in the prePCI TMP < 2 group vs 1.8% (N = 1) in the prePCI TMP > 2 group (P = 0.03) (Fig. 1).
Univariate predictors of death included advanced age (P = .005), admission Troponin T (P = .04), final visual TDVII flow (P < .001), Admission TMP grade (P < .001), postPCI TMP grade (P < .001), glucose levels (P = .002), WBC (P < .001), left ventricular ejection fraction (P < .001), peripheral vascular disease (P < .001), systolic blood pressure (P = .01), left anterior descending artery territory AMI (P = .01), and use of intraaortic balloon pump (P < .001) (Table II).
The multivariate logistic regression analysis found that advanced age (P < .001), use of intraaortic balloon pump (P < .001), and admission white blood cell counts (P = .01) were independently associated with inhospital and 30day death (Beta 0.333) (Table II).
Discussion
Impaired myocardial blood flow after AMI is a result of multiple insults including platelet/ thrombus microaggregate embolization combined with humoral factors derived from fibrinolysis (increased thrombin) and platelets (adenosine, serotonin, thromboxane A2). Inflammation and reperfusion injury may also exacerbate the problem by increasing neutrophil capillary plugging, liberating free radicals, and increasing capillary permeability, resulting in tissue edema and further deterioration of myocardial perfusión.36,37 Ischemic injury secondary to microvascular obstruction may be amplified in patients with an enhanced inflammatory milieu. In patients undergoing fibrinolysis as primary treatment for AMI, increased levels of CRP were associated with either death or postinfarction complications.21,2325 Our results suggest that patients with AMI have very high levels of hsCRP on admission, reflecting an increased inflammatory status. However, this did not translate into lower admission TMP levels.
Elevated WBC levels constitute another unspecific marker of inflammation.17,38 WBCs make a major contribution to the rheologic properties of blood by altering its adhesive properties under stress (including the stress of ischemia) and participate in endothelial injury, both acutely and chronically, by adhering to endothelium and damaging it with toxic oxygen compounds and proteolytic enzymes.39 Our results confirm the previously observed link of elevated WBC and death. The mechanism of this association remains uncertain. It suggests that other inflammatory stimuli, beyond CRP, are present. Various mechanisms may be perpetuating the inflammatory response including interleukin (IL)l, IL6, TNFα, adhesion molecules, and platelets.4042 These factors have a proinflammatory capacity that may up regulate and amplify a multitude of interactions that result in an increase in substances such as fibrinogen and PAI1, promoting adhesion of neutrophils and ultimately regulate gene expression of key proteins that potentiate the inflammatory cascade.43,44
Age has been related to poor outcome in AMI patients undergoing PCI.45 Our results confirm this observation. Patients that needed an intraaortic balloon pump had worse outcome suggesting that this cohort possibly was hemodynamically unstable, and therefore, at higher risk. As previously described, admission glucose was also associated with death as univariate variable. This has been associated to low myocardial perfusión, impairing left ventricular function thus worsening the outcome.30,46 Interestingly, the presence of peripheral vascular disease was also associated to death, reflecting the extent of cardiac and extracardiac atherosclerotic disease.47
Limitations
The present study should be interpreted in the light of the following limitations. This is not a randomized trial, with all the inherent potential confounding effects of an observational study. TMP grade is a subjective assessment of microcirculation, and the interobserver variation may bias the results, although the rate of concordance between observers in this study was 98%. The monitoring of other inflammatory markers, such as IL6, could have added more robust evidence of other inflammatory pathways associated with poor outcome. The time of onset and size of the myocardial infarction may also increase the CRP levels; these factors were not available in our database, therefore we were not able to include them in our analysis.
Conclusions
HsCRP levels were not significantly different between patients with or without a patent microcirculation before undergoing PCI. An increased inflammatory milieu, not reflected by CRP elevation alone, possibly mediates microcirculation impairment.
References
1. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, et al: Association between Admission White Blood Cell Count and OneYear Mortality in Patients with Acute Coronary Syndromes. Am J Med 2003; (115): 318321. [ Links ]
2. Yen MH, Topol EJ: Atheromatous Showers, Periprocedural Myocardial Infarction, and Fatality. Am Heart J 2003; (145): 933935. [ Links ]
3. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of CReactive Protein and Coronary Heart Disease in the Mrfit Nested CaseControl Study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; (144): 537547. [ Links ]
4. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al: CReactive Protein Is a Potent Predictor of Mortality Independently of and in Combination with Troponin T in Acute Coronary Syndromes: A Timi 11a Substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; (31): 14601465. [ Links ]
5. Abdelmouttaleb I, Danchin N, Ilardo C, AimoneGastin I, Angioi M, Lozniewski A, et al: CReactive Protein and Coronary Artery Disease: Additional Evidence of the Implication of an Inflammatory Process in Acute Coronary Syndromes. Am Heart J 1999; (137): 346351. [ Links ]
6. Albert MA, Ridker PM: The Role of CReactive Protein in Cardiovascular Disease Risk. Curr Cardiol Rep 1999; (1): 99104. [ Links ]
7. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al: CReactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy MiddleAged Men: Results from the Monica (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; (99): 237242. [ Links ]
8. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG: CReactive Protein Is a Strong but Nonspecific Risk Factor of Fatal Stroke in Elderly Persons. Arterioscler Thromb Vase Biol 2000; (20): 10471051. [ Links ]
9. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al: CReactive Protein: Relation to Total Mortality, Cardiovascular Mortality and Cardiovascular Risk Factors in Men. Eur Heart J 2000; (21): 15841590. [ Links ]
10. Strandberg TE, Tilvis RS: CReactive Protein, Cardiovascular Risk Factors, and Mortality in a Prospective Study in the Elderly. Arterioscler Thromb Vase Biol 2000; (20): 10571060. [ Links ]
11. Guijarro C: HighSensitivity CReactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation 2001; (104): E127. [ Links ]
12. Kanda T: CReactive Protein (Crp) in the Cardiovascular System. Rinsho Byori 2001; (49): 395401. [ Links ]
13. Rifai N, Ridker PM: HighSensitivity CReactive Protein: A Novel and Promising Marker of Coronary Heart Disease. Clin Chem 2001; (47): 403411. [ Links ]
14. Ridker PM: HighSensitivity CReactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation 2001; (103): 18131818. [ Links ]
15. Auer J, Berent R, Lassnig E, Eber B: CReactive Protein and Coronary Artery Disease. Jpn Heart J 2002; (43): 607619. [ Links ]
16. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, et al: HighSensitivity CReactive Protein in the Prediction of Coronary Events in Patients with Premature Coronary Artery Disease. Am Heart J 2002; (144): 449455. [ Links ]
17. Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM: The Association between White Blood Cell Count and Acute Myocardial Infarction Mortality in Patients > or = 65 Years of Age: Findings from the Cooperative Cardiovascular Project. J Am Coll Cardiol 2001; (38): 16541661. [ Links ]
18. Kroop IG, Shackman NH: Level of CReactive Protein as a Measure of Acute Myocardial Infarction. Proc Soc Exp Biol Med 1954; (86): 9597. [ Links ]
19. Kushner I, Broder ML, Karp D: Control of the Acute Phase Response. Serum CReactive Protein Kinetics after Acute Myocardial Infarction. J Clin Invest 1978; (61): 235242. [ Links ]
20. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J: Serum Levels of Acute Phase and Cardiac Proteins after Myocardial Infarction, Surgery, and Infection. Br Heart J 1982; (48): 352356. [ Links ]
21. Pietila K, Harmoinen A, Poyhonen L, Koskinen M, Heikkila J, Ruosteenoja R: Intravenous Streptokinase Treatment and Serum CReactive Protein in Patients with Acute Myocardial Infarction. Br Heart J 1987; (58): 225229. [ Links ]
22. Pietila K, Harmoinen A, Teppo AM: Acute Phase Reaction, Infarct Size and inHospital Morbidity in Myocardial Infarction Patients Treated with Streptokinase or Recombinant Tissue Type Plasminogen Activator. Ann Med 1991; (23): 529535. [ Links ]
23. Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M: Serum CReactive Protein and Infarct Size in Myocardial Infarct Patients with a Closed Versus an Open InfarctRelated Coronary Artery after Thrombolytic Therapy Eur Heart J 1993; (14): 915919. [ Links ]
24. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al: The Prognostic Value of CReactive Protein and Serum Amyloid a Protein in Severe Unstable Angina. N Engl J Med 1994; (331): 417424. [ Links ]
25. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI: Serum CReactive Protein Concentration in Acute Myocardial Infarction and Its Relationship to Mortality During 24 Months of Followup in Patients under Thrombolytic Treatment. Eur Heart J 1996; (17): 13451349. [ Links ]
26. Gheno G, Libardoni M, Zeppellini R, Cucchini F: CReactive Protein on Admission as a Predictor of inHospital Death in the Elderly with Acute Myocardial Infarction. Cardiología 1999; (44): 10231028. [ Links ]
27. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, et al: CReactive Protein as a Marker for Cardiac Ischemic Events in the Year after a First, Uncomplicated Myocardial Infarction. Am J Cardiol 1999; (83): 15951599. [ Links ]
28. Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD, et al: CReactive Protein Levels on Admission Are Associated with Response to Thrombolysis and Prognosis after StSegment Elevation Acute Myocardial Infarction. Am Heart J 2002; (144): 782789. [ Links ]
29. Auer J, Berent R, Eber B, Tanaka A, Sano T, Namba M, et al: CReactive Protein in Patients with Acute Myocardial Infarction. Circulation 2004; (109): E20. [ Links ]
30. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al: Impact of Acute Hyperglycemia on Left Ventricular Function after Reperfusion Therapy in Patients with a First Anterior Wall Acute Myocardial Infarction. Am Heart J 2003; (146): 674678. [ Links ]
31. Kirtane AJ, Bui A, Murphy SA, Barron HV, Gibson CM: Association of Peripheral Neutrophilia with Adverse Angiographic Outcomes in StElevation Myocardial Infarction. Am J Cardiol 2004; (93): 532536. [ Links ]
32. Wong CK, French JK, Gao W, White HD: Relationship between Initial White Blood Cell Counts, Stage of Acute Myocardial Infarction Evolution at Presentation, and Incidence of Thrombolysis in Myocardial Infarction3 Flow after Streptokinase. Am Heart J 2003; (145): 95102. [ Links ]
33. Marfella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis U, Romano C, et al: Effects of Stress Hyperglycemia on Acute Myocardial Infarction: Role of Inflammatory Immune Process in Functional Cardiac Outcome. Diabetes Care 2003; (26): 31293135. [ Links ]
34. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al: Relationship of Timi Myocardial Perfusion Grade to Mortality after Administration of Thrombolytic Drugs. Circulation 2000; (101): 125130. [ Links ]
35. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E: Relationship of the Timi Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to LongTerm Outcomes after Thrombolytic Administration in Acute Myocardial Infarction. Circulation 2002; (105): 19091913. [ Links ]
36. Mukherjee D, Moliterno DJ: Achieving TissueLevel Perfusion in the Setting of Acute Myocardial Infarction. Am J Cardiol 2000; (85): 39C46C. [ Links ]
37. Mehta JL, Nichols WW, Mehta P: Neutrophils as Potential Participants in Acute Myocardial Ischemia: Relevance to Reperfusion. J Am Coll Cardiol 1988; (11): 13091316. [ Links ]
38. Brown DW, Giles WH, Croft JB: White Blood Cell Count: An Independent Predictor of Coronary Heart Disease Mortality among a National Cohort. J Clin Epidemiol 2001; (54): 316322. [ Links ]
39. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormancy JA: Leukocytes and the Risk of Ischemic Diseases. JAMA 1987; (257): 23182324. [ Links ]
40. Furman MI, Becker RC, Yarzebski J, Savegeau J, Gore JM, Goldberg RJ: Effect of Elevated Leukocyte Count on inHospital Mortality Following Acute Myocardial Infarction. Am J Cardiol 1996; (78): 945948. [ Links ]
41. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al: Increased Platelet Reactivity and Circulating MonocytePlatelet Aggregates in Patients with Stable Coronary Artery Disease. J Am Coll Cardiol 1998; (31): 352358. [ Links ]
42. Rus HG, Niculescu F, Vlaicu R: Tumor Necrosis FactorAlpha in Human Arterial Wall with Atherosclerosis. Atherosclerosis 1991; (89): 247254. [ Links ]
43. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, et al: Elevated Plasma Interleukin6 Levels in Patients with Acute Myocardial Infarction. Am Heart J 1993; (126): 12991304. [ Links ]
44. Kushner I, Ganapathi M, Schultz D: The Acute Phase Response Is Mediated by Heterogeneous Mechanisms. Ann NY Acad Sci 1989; (557): 1929; discussion 2930. [ Links ]
45. Klein LW, Block P, Brindis RG, McKay CR, McCallister BD, Wolk M, et al: Percutaneous Coronary Interventions in Octogenarians in the American College of CardiologyNational Cardiovascular Data Registry: Development of a Nomogram Predictive of inHospital Mortality. J Am Coll Cardiol 2002; (40): 394402. [ Links ]
46. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al: Association between Hyperglycemia and the NoReflow Phenomenon inPatients with Acute Myocardial Infarction. J Am Coll Cardiol 2003; (41): 17. [ Links ]
47. Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, et al: Prior Peripheral Arterial Disease and Cerebrovascular Disease Are Independent Predictors of Adverse Outcome in Patients with Acute Coronary Syndromes: Are We Doing Enough? Results from the Orbofiban Thrombolysis in Myocardial Infarction (OpusTimi) 16 Study. Am Heart J 2003; (145): 622627. [ Links ]